Oxford Biomedica PLC

Major Shareholding Notification • Jan 28, 2022

National Storage Mechanism | Additional information

RNS Number : 0266A

Oxford Biomedica PLC

28 January 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BDFBVT43

Issuer Name

OXFORD BIOMEDICA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

Novo Holdings A/S

City of registered office (if applicable)

Hellerup

Country of registered office (if applicable)

Name	City of registered office	Country of registered office
Novo Nordisk Foundation	Hellerup	Denmark

4. Details of the shareholder

Name	City of registered office	Country of registered office
Novo Holdings A/S	Hellerup	Denmark

5. Date on which the threshold was crossed or reached

01-Jun-2021

6. Date on which Issuer notified

27-Jan-2022

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was	9.570000	0.000000	9.570000	8253000
crossed or reached
Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BDFBVT43	8253000	0	9.570000	0.000000
Sub Total 8.A	8253000		9.570000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

The position of Novo Holdings A/S in its previous TR-1 notification was 10.1%. This notification obligation has arisen as a result of issuances of shares by the issuer (and not a disposal of shares by Novo Holdings A/S) and is based upon the latest total voting rights announcement of the issuer dated 4 January 2022.

The qualifying instruments are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation.

12. Date of Completion

27-Jan-2022

13. Place Of Completion

London, United Kingdom

Contact name:	Natalie Walter
Contact telephone number:	01865 783000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLEADFPALPAEFA